Presenter: Dr Paola Neri, University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, Alberta

Minimal residual disease (MRD) is becoming an increasingly important part of myeloma care, but what does it actually mean for patients? This webinar will explain what MRD is, how it is measured, and why it matters. It will cover the different types of MRD testing, what an MRD-negative result does and does not mean, the current limitations of MRD testing, and how MRD may influence treatment decisions and the future of myeloma care in Canada. Whether you are newly diagnosed or have been living with myeloma for years, this webinar will provide practical, easy-to-understand information to help you better understand this evolving area of care.

Register here